Progression-Free Survival Common For Pregnant Women (Reuters Health)For pregnant HIV-infected women with access to highly active antiretroviral therapy (HAART), the medium-term postpartum prognosis is good, according to a report in the October 1st Journal of Acquired Immune Deficiency Syndromes.
October 27, 2006
Tyzeka Approved for Hepatitis B
The U.S. Food and Drug Administration (FDA) granted approval on Wednesday to Tyzeka? (telbivudine), a new treatment for chronic hepatitis B virus (HBV) infection.
October 26, 2006
Vaccine Series Safe In Children (Reuters Health)Pneumococcal conjugate vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV) appears to be safe and effective for certain HIV-infected children, researchers report in the October issue of the Pediatric Infectious Disease Journal.
October 24, 2006
Vulnerable HIV Patients Less Likely To Have Care (Reuters Health)Members of minority groups, who are most at risk of contracting HIV infection and most likely to be in greatest need of service, are also the individuals who are least likely to be receiving medical care in the U.S., investigators report.
October 23, 2006
Enfuvirtide As Rescue Therapy in Med-Experienced (Reuters Health)
Findings from a small study suggest that the fusion inhibitor
enfuvirtide (formerly T-20) is a useful therapeutic option for
multi-class experienced HIV-infected patients.
Enfuvirtide As Rescue Therapy (Reuters Health)
Findings from a small study suggest that the fusion inhibitor enfuvirtide (formerly T-20) is a useful therapeutic option for multi-class experienced HIV-infected patients.
October 19, 2006
AIDS activist with baboon marrow transplant dies
The California AIDS activist who received the first bone marrow
transplant from a baboon in a desperate bid to combat the disease died
this past week, his partner of 26 years said on Sunday.
October 16, 2006
Diet and Exercise Fight Metabolic Syndrome A new study suggests that improvements in diet and exercise can help manage some of the signs and symptoms of the "metabolic syndrome" in people with HIV.
AIDS Activist With Baboon Marrow Transplant Dies (Reuters Health)The California AIDS activist who received the first bone marrow transplant from a baboon in a desperate bid to combat the disease died this past week, his partner of 26 years said on Sunday.
October 11, 2006
Bacteria Protein Prevents HIV Entry (Reuters Health)
The binding domain from Porphyromonas gingivalis gingipain prevents cell entry by HIV-1, according to a report in the September issue of Antimicrobial Agents and Chemotherapy.
October 10, 2006
Tenofovir Prodrug Delays SHIV Infection (Reuters Health)
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
Course Of HIV Neurologic Disease Variable, Related To Platelet Count (Reuters Health)Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
October 06, 2006
Animal Study Indicates Alcohol May Accelerate HIV Progression (Reuters Health)Simian immunodeficiency virus (SIV) disease appears to progress more rapidly in rhesus macaques that have been regularly subjected to ethanol intoxication, researchers report. They say the effect could be similar in people infected with HIV.
October 05, 2006
Medecins Sans Frontieres Founder Wants Stronger WHO (Reuters Health)The United Nations cannot take a backseat to private philanthropic foundations and needs more money to combat diseases like malaria and tuberculosis, the French candidate to lead the World Health Organisation (WHO) said on Thursday.
Boosted Atazanavir Of Mixed Benefit In Pediatric HIV (Reuters Health)Switching to a once daily-regimen including ritonavir-boosted atazanavir appears helpful in some HIV-infected children, but has led to unexpected virological failure in others, according to French researchers
October 03, 2006
ICAAC: Trizivir vs. Reyataz/Combivir A new study suggests that 48 weeks of treatment with Trizivir® is comparable to a protease inhibitor-based regimen.
October 02, 2006
ICAAC: Norvir-Boosted Lexiva vs. Reyataz Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that both drugs have similar effectiveness.
